SG11202100985QA - Ophthalmic compositions and methods for the treatment of eye disorders and skin diseases - Google Patents
Ophthalmic compositions and methods for the treatment of eye disorders and skin diseasesInfo
- Publication number
- SG11202100985QA SG11202100985QA SG11202100985QA SG11202100985QA SG11202100985QA SG 11202100985Q A SG11202100985Q A SG 11202100985QA SG 11202100985Q A SG11202100985Q A SG 11202100985QA SG 11202100985Q A SG11202100985Q A SG 11202100985QA SG 11202100985Q A SG11202100985Q A SG 11202100985QA
- Authority
- SG
- Singapore
- Prior art keywords
- treatment
- methods
- skin diseases
- ophthalmic compositions
- eye disorders
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/42—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
- C07C237/26—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton of a ring being part of a condensed ring system formed by at least four rings, e.g. tetracycline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/03—Monocarboxylic acids
- C07C57/12—Straight chain carboxylic acids containing eighteen carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
- C07C63/33—Polycyclic acids
- C07C63/337—Polycyclic acids with carboxyl groups bound to condensed ring systems
- C07C63/34—Polycyclic acids with carboxyl groups bound to condensed ring systems containing two condensed rings
- C07C63/36—Polycyclic acids with carboxyl groups bound to condensed ring systems containing two condensed rings containing one carboxyl group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/46—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
- C07D339/02—Five-membered rings
- C07D339/04—Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201841032406 | 2018-08-29 | ||
PCT/IB2019/055828 WO2020044136A1 (en) | 2018-08-29 | 2019-07-09 | Ophthalmic compositions and methods for the treatment of eye disorders and skin diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202100985QA true SG11202100985QA (en) | 2021-03-30 |
Family
ID=69644060
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202100985QA SG11202100985QA (en) | 2018-08-29 | 2019-07-09 | Ophthalmic compositions and methods for the treatment of eye disorders and skin diseases |
Country Status (12)
Country | Link |
---|---|
US (1) | US20210188817A1 (de) |
EP (1) | EP3823603A4 (de) |
JP (1) | JP2021536439A (de) |
KR (1) | KR20210053926A (de) |
AU (1) | AU2019333020A1 (de) |
BR (1) | BR112021003452A2 (de) |
CA (1) | CA3110248A1 (de) |
IL (1) | IL280588A (de) |
MX (1) | MX2021001645A (de) |
SG (1) | SG11202100985QA (de) |
WO (1) | WO2020044136A1 (de) |
ZA (1) | ZA202100656B (de) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102636847B1 (ko) | 2020-09-18 | 2024-02-19 | 경북대학교 산학협력단 | 티아민 유도체를 포함하는 이식편대숙주질환 예방 또는 치료용 약학적 조성물 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1172110A3 (de) * | 2000-07-07 | 2003-09-17 | Basf Aktiengesellschaft | Verwendung von Liponsäure zur Verbesserung der Bioverfügbarkeit von Mineralsalzen |
US20020198210A1 (en) * | 2001-05-03 | 2002-12-26 | Allergan Sales Inc. | Alpha-2-adrenergic agonist/fatty acid compositions |
AU2002256471B2 (en) * | 2001-05-03 | 2007-05-24 | Allergan, Inc. | Compositions having enhanced pharmacokinetic characteristics |
US20040266776A1 (en) * | 2003-06-25 | 2004-12-30 | Gil Daniel W. | Methods of preventing and reducing the severity of stress-associated conditions |
WO2008144399A1 (en) * | 2007-05-18 | 2008-11-27 | Bausch & Lomb Incorporated | COMPLEXES COMPRISING α2-ADRENERGIC RECEPTOR AGONISTS AND COMPOSITIONS |
US20100203165A1 (en) * | 2008-08-01 | 2010-08-12 | Gerald Horn | Compositions and methods for treatment of disorders or conditions of the eye |
US8034813B2 (en) * | 2008-11-18 | 2011-10-11 | Bausch & Lomb Incorporated | Polymorphs of brimonidine pamoate |
EP2329849B1 (de) * | 2009-11-18 | 2015-04-29 | Galderma Research & Development | Kombination aus einem Alpha-2-Adrenozeptor-Agonisten und einem nichtsteroidalen entzündungshemmenden Mittel zur Behandlung oder Prävention einer Entzündungskrankheit der Haut |
HUE033143T2 (en) * | 2010-03-26 | 2017-11-28 | Galderma Res & Dev | Preparations containing brimonidine for the treatment of erythema |
US20120076738A1 (en) * | 2010-09-28 | 2012-03-29 | Michael Graeber | Combination treatment for dermatological conditions |
DK2755647T3 (en) * | 2011-09-12 | 2015-10-12 | Tassos Georgiou | Use of omega fatty acid for medical care |
AU2018369853B2 (en) * | 2017-11-17 | 2022-07-14 | Cellix Bio Private Limited | Compounds, compositions and methods for treatment of eye disorders and skin diseases |
-
2019
- 2019-07-09 SG SG11202100985QA patent/SG11202100985QA/en unknown
- 2019-07-09 CA CA3110248A patent/CA3110248A1/en active Pending
- 2019-07-09 BR BR112021003452-8A patent/BR112021003452A2/pt not_active IP Right Cessation
- 2019-07-09 US US17/250,756 patent/US20210188817A1/en active Pending
- 2019-07-09 WO PCT/IB2019/055828 patent/WO2020044136A1/en active Search and Examination
- 2019-07-09 JP JP2021510180A patent/JP2021536439A/ja active Pending
- 2019-07-09 MX MX2021001645A patent/MX2021001645A/es unknown
- 2019-07-09 EP EP19853601.3A patent/EP3823603A4/de not_active Withdrawn
- 2019-07-09 KR KR1020217009234A patent/KR20210053926A/ko not_active Application Discontinuation
- 2019-07-09 AU AU2019333020A patent/AU2019333020A1/en active Pending
-
2021
- 2021-01-29 ZA ZA2021/00656A patent/ZA202100656B/en unknown
- 2021-02-02 IL IL280588A patent/IL280588A/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2019333020A1 (en) | 2021-04-29 |
WO2020044136A1 (en) | 2020-03-05 |
US20210188817A1 (en) | 2021-06-24 |
EP3823603A4 (de) | 2022-12-07 |
AU2019333020A2 (en) | 2021-05-06 |
EP3823603A1 (de) | 2021-05-26 |
JP2021536439A (ja) | 2021-12-27 |
BR112021003452A2 (pt) | 2021-05-18 |
KR20210053926A (ko) | 2021-05-12 |
CA3110248A1 (en) | 2020-03-05 |
MX2021001645A (es) | 2021-05-12 |
ZA202100656B (en) | 2021-09-29 |
IL280588A (en) | 2021-03-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL262608A (en) | Combined treatment of eye disorders and inflammatory diseases | |
EP3749264C0 (de) | Lasertherapie zur behandlung und vorbeugung von augenkrankheiten | |
PT3377637T (pt) | Composições para uso em métodos para o tratamento de ferimentos, transtornos e doenças da pele | |
IL276383A (en) | Treatment of ophthalmological diseases | |
IL287280A (en) | Compounds and methods for the treatment of ocular disorders | |
EP3876712C0 (de) | Screening-verfahren für behandlungen von intraokulare krankheiten oder störungen | |
IL274234A (en) | Preparations and methods for the treatment of eye diseases | |
IL286636A (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES OR DISORDERS RELATED TO KRAS | |
ZA202006234B (en) | Compositions and methods for the treatment of neurological diseases | |
IL287802A (en) | Preparations and methods for the treatment of eye diseases | |
IL273531A (en) | Ophthalmic preparations containing latanoprost for use in the treatment of eye diseases | |
IL284344A (en) | Pharmaceutical preparations for the eyes and methods for the treatment of diseases of the surface of the eye | |
IL287264A (en) | Compounds and methods for the treatment of ocular disorders | |
EP4054713A4 (de) | Zusammensetzungen und verfahren zur behandlung oder vorbeugung von hautkrankheiten und störungen mit lekti | |
IL289405A (en) | Personalized treatment of eye diseases | |
ZA202002075B (en) | Compounds, compositions and methods for treatment of eye disorders and skin diseases | |
EP3713553A4 (de) | Zusammensetzungen und verfahren zur behandlung von augenkrankheiten | |
EP3644966A4 (de) | Behandlung und diagnose von störungen der augenoberfläche | |
SG11202012473UA (en) | Ophthalmic compositions and methods for the treatment of eye disorders | |
EP4010075A4 (de) | Verfahren zur behandlung von apoc3-assoziierten erkrankungen und störungen | |
ZA202003944B (en) | Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye | |
IL280588A (en) | Ophthalmic compositions and methods for treating eye problems and skin diseases | |
IL282898A (en) | Ophthalmic compounds and methods for treating skin and eye diseases | |
PL3515409T3 (pl) | Kompleks i kompozycje do leczenia chorób okulistycznych i dermatologicznych | |
EP3787749A4 (de) | Verfahren zur behandlung von netzhauterkrankungen |